Activate Now
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

How One LLND Treats Lyme disease and Co-infections Using Natural Medicine

SURVEY RESULTS: Has Your Illness Affected What You Eat?

New depression diagnosis and treatment

Surprising Benefits of Cinnamon

Specific vitamin D levels linked to heart problems

A Sleep Intervention For Children With Autism: A Pilot Study

Higher vitamin D levels may be protective against acute rhinosinusitis

Real Life as a Mom with Chronic Illness

Saffron reduces oxidative stress in metabolic syndrome patients

Print Page
Email Article

Effects of Sodium Oxybate for Fibromyalgia Maintained in Long-Term Study

  [ 12 votes ]   [ 2 Comments ] • December 22, 2013

Note: You may read the full text of this article free HERE.

Editor's comment: In October 2010, the FDA turned down Jazz Pharmaceuticals request for approval of sodium oxybate for the treatment of fibromyalgia, citing safety concerns. They expressed particular concerns about the potential for abuse or misuse of the medication. 

Sodium oxybate is currently approved for the treatment of excessive daytime sleepiness and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy. It's use is monitored by an extremely stringent safety plan – an even more restrictive plan than is used for opioids.  Sodium oxybate is classified as a Schedule III drug and its distribution is restricted through the Patient Success Program.   It can only be purchased from one central, mail-order pharmacy and patients are first required to read a letter and brochure as well as watch a video about the medication.

One of the reasons the FDA has such serious concerns is likely because sodium oxybate, also known as gamma-hydroxybutyrate (GHB), is known to have been used as a date rape drug in the past.  In an effort to address the FDA's concerns, Jazz Pharmaceuticals is conducting additional studies on the safety and efficacy of sodium oxybate for FM.  This study looked at the long-term effectiveness and tolerability of the drug.

Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia.

By Michael Spaeth, et al.


INTRODUCTION: The long-term safety and therapeutic response of sodium oxybate (SXB) in fibromyalgia syndrome (FM) patients were assessed for a combined period of up to 1 year in a prospective, multicenter, open-label, extension study in patients completing 1 of 2 phase 3 randomized, double-blind, controlled, 14-week trials that examined the efficacy and safety of SXB 4.5 g, SXB 6 g, and placebo for treatment of FM.

METHODS: This extension study comprised an additional 38 weeks of treatment and was carried out at 130 clinical sites in 7 countries. Initial entry criteria for the previous 2 double-blind clinical trials required that patients aged ? 18 years met the American College of Rheumatology 1990 criteria for FM, had a body mass index (BMI) < 40 kg/m2, and had a score ? 50 on a 100-mm pain visual analog scale (VAS) at baseline. All patients began treatment in the extension study with SXB 4.5 g/night (administered in 2 equally divided doses) for at least 1 week, followed by possible serial 1.5 g/night dose increases to 9 g/night (maximum) or reductions to 4.5 g/night (minimum).

RESULTS: Of the 560 FM patients enrolled in this extension study, 319 (57.0%) completed the study. The main reason for early discontinuation was adverse events (AEs; 23.0% of patients). Patients were primarily middle-aged (mean 46.9?±?10.8 years), female (91.1%), white (91.4%), with a mean duration of FM symptoms of 9.9?±?8.7 years.

  • Serious AEs were experienced by 3.6% of patients.

  • The most frequently reported AEs (incidence ? 5% at any dose or overall) were nausea, headache, dizziness, nasopharyngitis, vomiting, sinusitis, diarrhea, anxiety, insomnia, influenza, somnolence, upper respiratory tract infection, muscle spasms, urinary tract infection, and gastroenteritis viral.

  • Maintenance of SXB therapeutic response was demonstrated with continued improvement from controlled-study baseline in pain VAS, Fibromyalgia Impact Questionnaire (FIQ) total scores, and other measures.

  • Responder analyses showed that 68.8% of patients achieved ? 30% reduction in pain VAS and 69.7% achieved ? 30% reduction in FIQ total score at study endpoint.

CONCLUSIONS: The long-term safety profile of SXB in FM patients was similar to that in the previously reported controlled clinical trials. Improvement in pain and other FM clinical domains was maintained during long-term use.

Source: Arthritis Research & Therapy, November 11, 2013. By Michael Spaeth, Cayetano Alegre, Serge Perrot, Youyu Grace Wang, Diane R Guinta, Sarah Alvarez-Horine, Irwin Jon Russell and the Sodium Oxybate Fibromyalgia Study Group.

Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Vitamin D3 Extreme™ Mitochondria Ignite™ with NT Factor®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments Post a Comment

Better than what's out there
Posted by: MarcieRose
Jan 29, 2014
The response to this compound is equal to or better than current approved treatments. Further, the pain reductions seen may well be due to the increase in deep, restorative sleep that Sodium oxybate promotes. There simply has to be a way to get the FDA to reconsider this compound.
Reply Reply
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Subscribe Now!
Receive up-to-date ME/CFS, Fibromyalgia & Lyme Disease treatment and research news
 Privacy Guaranteed  |  View Archives

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root
SAD? Coping with Seasonal Affective Disorder
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew

What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Causes
Fibromyalgia Treatments
Fibromyalgia Diet
Fibromyalgia Medications
M.E. & CFS
What is M.E./CFS?
M.E./CFS Diagnosis
M.E./CFS Symptoms
M.E./CFS Causes
M.E./CFS Treatments
M.E./CFS Diet
M.E./CFS Medications
What is Lyme Disease?
Lyme Disease Diagnosis
Lyme Disease Symptoms
Lyme Disease Causes
Lyme Disease Treatments
Lyme Disease Diet
Lyme Disease Medications
M.E. & CFS
Lyme Disease
General Health
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing